|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current assets | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Marketable securities | |||||||||||||||
| Accounts receivable, net | |||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||
| Tax receivable | |||||||||||||||
| Inventory, net | |||||||||||||||
| Total current assets | |||||||||||||||
| Property and equipment, net | |||||||||||||||
| Operating lease right of use assets, net | |||||||||||||||
| Deferred tax assets, net | |||||||||||||||
| Other non-current assets | |||||||||||||||
| Total assets | |||||||||||||||
| Liabilities and shareholders’ equity | |||||||||||||||
| Current liabilities | |||||||||||||||
| Accounts payable | |||||||||||||||
| Accrued expenses and other current liabilities | |||||||||||||||
| Deferred revenue, current | |||||||||||||||
| Operating lease liabilities, current | |||||||||||||||
| Interest-bearing loans and borrowings, current | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Accrued expenses, non-current | |||||||||||||||
| Deferred revenue, non-current | |||||||||||||||
| Operating lease liabilities, non-current | |||||||||||||||
| Interest-bearing loans and borrowings | |||||||||||||||
| Total liabilities | |||||||||||||||
| Shareholders’ equity | |||||||||||||||
| Ordinary shares (voting and non-voting), £0.002 par value, authority to allot up to a maximum nominal value of £149,303 and £149,633 shares as of September 30, 2026 and December 31, 2025, respectively, and 51,635,820 and 50,689,271 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively. | |||||||||||||||
| Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of September 30, 2026 and December 31, 2025. | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||
| Total shareholders' equity | |||||||||||||||
| Total liabilities and shareholders' equity | |||||||||||||||
| Common stock, shares outstanding (in shares) | |||||||||||||||
Loading...